Flavobacterium columnar recombinant protein as well as preparation method and application thereof

By fusing the immunogenic protein of Floxobacterium columnar with Mandarin fish type I interferon, it was prepared into a recombinant protein oral vaccine, which solved the problem of difficulty in operation and low antigen delivery efficiency in fish immunization methods, and achieved efficient and safe Fish immune protection.

CN118955731APending Publication Date: 2024-11-15WUHAN HUAYANG ANIMAL PHARMA
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410930750.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-11
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The existing fish immunization methods have problems such as strong irritation, difficulty in operation, unstable drug residues and absorption effects of immersion vaccines. In addition, the antigen delivery efficiency in the development of oral vaccines for fish is low, making it difficult to ensure the immune effect.

Method used

The recombinant protein fused by the immunogenic protein of Floxobacterium columnar and the I-type interferon of the mandarin fish was prepared into an oral vaccine and mixed into feed to achieve mucosal immunity.

Benefits of technology

It has achieved effective protection of mandarin fish, reduced mortality, simple operation, high safety, low cost, stable immune effect, and avoided drug residues and stress responses.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118955731A_ABST
    Figure CN118955731A_ABST
Patent Text Reader

Abstract

The invention provides a flavobacterium columnar recombinant protein as well as a preparation method and application thereof, and belongs to the technical field of prevention and treatment of diseases of aquatic animals. The amino acid sequence of the flavobacterium columnar recombinant protein is as shown in SEQ ID No. 1. The recombinant protein is obtained by constructing a flavobacterium columnar immunogenic protein (GldK) and a mandarin fish I-type interferon related sequence. The gene of the recombinant protein is connected into a plasmid to construct a recombinant plasmid, and the recombinant plasmid is subjected to the steps of cloning, positive screening, re-extraction, enlarged culture, inducible expression and the like to obtain the recombinant protein. The recombinant protein is prepared into an oral vaccine, and the oral vaccine is mixed into feed for feeding for immunization, so that the morbidity and death rate of mandarin fish is reduced, and the effect of mucosa immunization is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of aquatic animal disease prevention and treatment, in particular to the technical field of fish columnar disease vaccine development, and specifically to a recombinant protein of Flavobacterium columnaris and a preparation method and application thereof. Background Art

[0002] Flavobacterium columnare is a common aquatic pathogen, widely distributed in ponds, lakes, rivers and other water bodies. It has a very wide host range and can infect fish from multiple families including Cyprinidae, Perchidae, Siluridae, Salmonidae, Heliothis, and Mugilidae. Almost all freshwater fish are sensitive to it. Columnar disease caused by Flavobacterium columnare, also known as bacterial gill rot, is a bacterial disease with a very high incidence rate in freshwater fish. It mainly harms grass carp (Ctenopharyngodon idellus), mandarin fish (Siniperca chuatsi), carp (Cyprinus carpio), crucian carp (Carassius auratus) and other fish, causing significant economic losses to my country's aquaculture industry.

[0003] At present, the prevention and control methods for columnar disease include optimizing the aquaculture water environment and cultivating disease-resistant varieties, using chemical disinfectants to disinfect aquaculture water and aquatic animals, using antibiotics to mix bait for feeding, and immunization. However, although chemical disinfectants and antibiotics can control the outbreak of columnar disease to a certain extent, long-term use will lead to the production of drug-resistant strains, food safety issues caused by drug residues in aquatic products, and adverse effects on the balance of the aquatic ecosystem. Therefore, the prevention and control of columnar disease through immunization has become a research focus in the industry.

[0004] At present, the main methods of immunizing fish are injection vaccination and immersion vaccination. The injection vaccination method is highly irritating and may cause stress reactions and inflammation in fish due to pain. The operation is difficult and requires operators with very good professional skills. In particular, large-scale injections require more professionals and equipment, and the operating cost is too high. The immersion vaccination method is more complicated to control the concentration of vaccine exposure to fish, which is prone to waste or drug residues. The drugs in the immersion process may have adverse effects on the water environment. In addition, different fish may have different absorption effects on immune immersion, and the immune effect is difficult to guarantee. Therefore, it is necessary to develop oral vaccines for fish.

[0005] The current obstacle to the development of oral vaccines for fish is how to deliver antigens to the intestinal immune system more efficiently. Common adjuvants for oral vaccines for fisheries include polymeric microspheres, immune complex stimulators, cholera toxin, Escherichia coli heat-labile enterotoxin and cytokines. The use of these adjuvants requires consideration of the cumbersomeness of adjuvant production operations, usage, price, and external environmental factors, as well as the safety, efficiency, and toxic side effects of the overall vaccine. An ideal adjuvant should specifically assist the vaccine in stimulating the immune system without causing side effects to animals. Immune adjuvants can not only change the type of immunoglobulin, but also change the intensity of immune response, enhance immune response, induce the body to produce specific immunity, eliminate immune tolerance produced by the body, and reduce immune side effects. Type I and type II interferons found in fish are cytokines that play an important role in innate and acquired immunity, and have multiple functions such as inhibiting cell division, regulating immunity, antiviral, and anti-tumor. However, there are no reports of using fish interferon as an immune adjuvant to successfully prepare oral vaccines and achieve effective immune effects. Summary of the invention

[0006] Based on the above problems, the present invention provides a recombinant protein of Flavobacterium columnaris. The recombinant protein is obtained by fusing the immunogenic protein (GldK) of Flavobacterium columnaris with type I interferon of mandarin fish, and the gene of the recombinant protein is recombinantly expressed in Escherichia coli, and the recombinantly expressed protein is prepared into an oral vaccine, and the oral vaccine is mixed into feed for immunization, thereby reducing the morbidity and mortality of mandarin fish and achieving the effect of mucosal immunity.

[0007] Specifically, the present invention adopts the following technical solutions to achieve the above objectives:

[0008] A first aspect of the present invention provides a recombinant protein of Flavobacterium columnaris, the amino acid sequence of the recombinant protein of Flavobacterium columnaris is shown in SEQ ID No.1.

[0009] The second aspect of the present invention provides a nucleic acid molecule encoding the recombinant protein of Flavobacterium columnaris.

[0010] In a preferred embodiment, the nucleotide sequence of the nucleic acid molecule is shown as SEQ ID No.2.

[0011] The third aspect of the present invention provides a recombinant plasmid, which comprises the nucleic acid molecule.

[0012] A fourth aspect of the present invention provides a host cell, wherein the host cell comprises the recombinant plasmid, or the nucleic acid molecule is integrated into the genome of the host cell.

[0013] The fifth aspect of the present invention provides a method for preparing a recombinant protein of Flavobacterium columnaris, comprising the following steps: constructing the recombinant plasmid, and obtaining the recombinant protein of Flavobacterium columnaris after transformation, culture, positive screening, plasmid re-extraction, re-transformation, expanded culture, and induced expression of the recombinant plasmid.

[0014] In a preferred embodiment, the recombinant plasmid is obtained by connecting the nucleic acid molecule to plasmid pET-32a.

[0015] The sixth aspect of the present invention is to provide the use of the preparation method of the recombinant protein of Flavobacterium columnaris or the nucleic acid molecule or the recombinant plasmid or the host cell or the recombinant protein of Flavobacterium columnaris in the preparation of the subunit oral vaccine of Flavobacterium columnaris.

[0016] The seventh aspect of the present invention is to provide a subunit oral vaccine of Flavobacterium columnaris, wherein the oral vaccine comprises the recombinant protein of Flavobacterium columnaris.

[0017] The eighth aspect of the present invention is to provide the use of the subunit oral vaccine of Flavobacterium columnaris in the preparation of products for preventing and / or treating columnar disease in aquatic animals.

[0018] Compared with the prior art, the technical solution of the present invention has the following beneficial effects: (1) Different from the existing fishery vaccine adjuvants, which have various problems such as complicated production operation, high price, poor safety, large toxic side effects, and external environmental influence, the adjuvant of the present invention is constructed by using the effective fragment of mandarin fish interferon, which does not involve the above factors that need to be considered for conventional adjuvants, and has the advantages of simple operation, high safety, stable immune effect, and high production efficiency. (2) The present invention successfully prepared a subunit oral vaccine of Flavobacterium columnaris, and the protection efficiency of mandarin fish infected with Flavobacterium columnaris reached 69%. (3) The oral immunization vaccination method of the present invention is more convenient to use than injection immunization and immersion immunization vaccines, simple operation, more labor-saving, and cost-saving, and is not limited by the size of the fish, and will not cause stress or even harm to the fish. (4) Inactivated vaccines are expensive and may cause loss of viral antigens and destruction of antigen structure during preparation. Nucleic acid DNA may induce autoimmune reactions, which may lead to immune tolerance of the body to antigens. The vaccine antigen prepared in the present invention is a protein. Compared with other new vaccines (such as live vector vaccines, nucleic acid vaccines, and gene-deficient vaccines), it does not contain live virus components, and there is no possibility of virus transmission during production and use. It also has strong immune specificity, good repeatability, low cost, and safer vaccines, without biosafety issues. The vaccine antigen prepared in the present invention is a neutralizing antigen protein, rather than an inactivated or attenuated vaccine, which further ensures that the vaccine is safe and reliable. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1The figure is the result of agarose gel electrophoresis of the gene encoding the recombinant protein GldK-IFN Domain after restriction digestion, wherein M is the DNA marker lane, and 1 and 2 are the target gene lanes;

[0020] Figure 2 The agarose gel electrophoresis results of pET-32a gene digested with restriction endonucleases, where M is the DNA marker lane, 1 is the lane of the gene before digestion, and 2 is the lane of the gene after digestion;

[0021] Figure 3 This is the colony picture after the recombinant plasmid was transformed into DH5α competent cells and cultured for 12 hours;

[0022] Figure 4 This is the result of PCR identification of positive monoclonal colonies;

[0023] Figure 5 This is the colony picture after the recombinant plasmid was transformed into BL21 competent cells and cultured for 12 hours;

[0024] Figure 6 This is a WB identification image of the recombinant protein obtained after induction and expression;

[0025] Figure 7 This is the mortality curve of mandarin fish after artificial infection with Flavobacterium columnaris. DETAILED DESCRIPTION

[0026] The following content is combined with the embodiments to clearly and completely describe the technical solution of the present application so that those skilled in the art can fully understand the present application. Obviously, the described embodiments are only some preferred embodiments of the present application, rather than all embodiments. Any equivalent transformation or substitution made to the following implementation modes by those of ordinary skill in the art without creative work belongs to the protection scope of the present application.

[0027] The materials and reagents used in this application come from the following sources:

[0028] Plasmid DNA minipreparation kit, ligase, 2× Rapid Taq Master Mix (containing dye and Taq DNA polymerase), DNA marker, and HRP-conjuated Mouse anti His-Tag mAb antibody were purchased from Yubao Bioengineering (Dalian) Co., Ltd. (Dalian TaKaRa Company).

[0029] LB medium: 10 g tryptone, 5 g yeast extract, 10 g sodium chloride (add 20 g agar powder when preparing the plate), dissolved in ddH2O, 1 mol / L NaOH to adjust the pH to 7.0-7.5, make up to 1000 mL, sterilize under high pressure steam at 121°C for 20 min, and store at 4°C for later use.

[0030] The SDS-PAGE gel used for WB (Western Blot) identification of recombinant proteins was prepared using the SDS-PAGE gel preparation kit (P0012A) produced by Shanghai Biotech Biotechnology Co., Ltd., and the electrophoresis buffer was the SDS-PAGE electrophoresis buffer (P0014A / P0014B) produced by Shanghai Biotech Biotechnology Co., Ltd. HRP-conjugated Mouse antiHis-Tag mAb (AE028) was purchased from Wuhan Abotek Biotechnology Co., Ltd. The main components of TBST buffer: 20mM Tris, 150mM NaCl were dissolved in 900mL ddH2O, the pH was adjusted to 7.4, and the solution was fixed to 1L, and then 1mL Tween20 was added.

[0031] Example 1

[0032] A method for preparing a recombinant protein of Flavobacterium columnaris comprises the following steps:

[0033] 1.1. Preparation of recombinant protein GldK-IFN Domain

[0034] The gene sequence of immunogenic protein gliding motility lipoprotein Gld K of Flavobacterium columnaris (NCBI Reference Sequence: WP_060383262.1) was downloaded from Genbank, and the position of the signal peptide was analyzed using online software (LipoP1.0Server) to obtain the mature peptide sequence of the gliding motility lipoprotein GldK gene. According to the preference of Escherichia coli codons, the gene sequence fragment of immunogenic protein gliding motility lipoprotein GldK of Flavobacterium columnaris and the gene fragment of interferon phi 3 of mandarin fish (NCBI Sequence ID: XP_044037313.1) were used to prepare the recombinant protein GldK-IFN Domain by genetic engineering. The amino acid sequence of the recombinant protein GldK-IFN Domain is shown in SEQ ID No.1, and the nucleotide sequence encoding the recombinant protein GldK-IFN Domain is shown in SEQ ID No.2.

[0035] 1.2. Construction of recombinant plasmid

[0036] The gene sequence encoding the recombinant protein GldK-IFN Domain was digested with BamHI and EcoRI restriction enzymes. The digestion results are shown in Figure 1 As shown. Figure 1 The agarose gel electrophoresis band of the GldK-IFN Domain target gene can be seen on the graph. The plasmid pET-32a (purchased from Biolabs, catalog number: QN1045) was digested with the same BamHI and EcoRI restriction endonucleases. The digestion results are shown in Figure 2 As shown, Figure 2 The upper band 1 is the uncut band, and the upper band 2 is the cut band. The cut product of the gene encoding the recombinant protein GldK-IFN Domain (target gene) and the cut pET-32a (i.e., linearized plasmid) were ligated by enzyme to obtain the shuttle plasmid pET32a-GldK-IFN (i.e., recombinant plasmid).

[0037] Enzyme digestion reaction system: Prepare on ice, 2 μL BamHI (Thermo Scientific TM , FastDigest BamHI, Catalog No.: FD0055), 2μL EcoRI (Thermo Scientific TM , FastDigest EcoRI, Catalog No.: FD 0274), 2 μL 10× Buffer, 13 μL linearized plasmid or target gene, ddH2O to a total volume of 50 μL. Incubate in a 37°C water bath for overnight digestion.

[0038] Construction of recombinant plasmids by one-step cloning:

[0039] Prepare the reaction system on ice: 1 μL linearized plasmid, 3 μL target gene, 2 μL 5×CEII buffer, 1 μL Express II, and add ddH2O to a total volume of 10 μL. Use a pipette to gently mix (do not oscillate), centrifuge briefly, collect the reaction solution to the bottom of the tube, heat the lid at 47°C, and react at 37°C for 30 minutes.

[0040] 1.3. Transform the recombinant plasmid into the host cell for cloning and positive screening

[0041] 1.3.1. Transform the constructed recombinant plasmid pET32a-GldK-IFN into E. coli DH5α competent cells, shake the cells, apply 100 μL of the bacterial solution on the LB plate with Kana resistance, place it in the incubator, and culture it at 37℃ for 12 hours. The cultured colonies are as follows: Figure 3 shown.

[0042] 1.3.2 Colony identification: Pick 4 monoclonal bacteria from the colonies cultured in step 3 and perform PCR identification. The identification results are as follows: Figure 4 shown. Figure 4 1, 2, 3, and 4 are the target bands of 4 monoclonal colonies after PCR reaction and agarose gel electrophoresis. It can be seen from the figure that colony 1 is a positive clone.

[0043] The PCR reaction system (prepared on ice) is as follows: 5 μL 2×Rapid Taq Master Mix, 0.5 μL 0.5 μmol / L forward primer, 0.5 μL 0.5 μmol / L reverse primer, 1 μL bacterial solution, and ddH2O is added to make the total volume 10 μL. The sequences of the forward and reverse primers are shown in SEQ ID No. 3 and SEQ ID No. 4, respectively.

[0044] PCR reaction program: pre-denaturation at 95°C for 3 min; 95°C for 15 s, 60°C for 15 s, 72°C for 15 s / kb, for 30-35 cycles; 72°C for 5 min (thorough extension).

[0045] 1.4. Transformation of positively transformed bacteria into host cells for expression for expansion, induction of expression and purification

[0046] The No. 1 colony that passed the PCR identification was shaken for 8 hours, and the shuttle plasmid pET32a-GldK-IFN was extracted in small quantities using a DNA small-scale extraction kit. The concentration was detected to be 200 ng / μL. The extracted recombinant plasmid pET32a-GldK-IFN was transferred into the E. coli competent cell BL21, and 100 μL of the bacterial solution was spread on the LB plate with Kana resistance and cultured at 37°C for 12 hours. The cultured colonies were as follows: Figure 5 Pick a single clone colony on the plate and place it in 300 mL LB liquid medium containing Kana resistance, shake the culture at 37°C and 220 rpm for 8 h, add the culture solution to 50% glycerol (1:1 by volume), and freeze it at -20° for seed preservation.

[0047] 0.3 mL of the recombinant bacterial cultured with BL21 cells was placed in 300 mL of LB liquid medium containing kanamycin sulfate and cultured at 37°C and 220 rpm until the OD 600nm The concentration of IPTG (isopropyl-β-D-thiogalactoside) was 0.6-1.0, and the final concentration was 0.8 mM. The culture was continued at 37°C for 6 h, and the bacterial liquid was collected by centrifugation.

[0048] 1.5. Western Blot Identification of Recombinant Protein

[0049] Dissolve 1mg of dry bacteria in 1mL of pure water, mix well, take 5μL and add 5μL of 2×SDS-PAGE protein loading buffer, heat to 100℃ or in a boiling water bath for 10 minutes to fully denature the protein, and centrifuge at 12000rpm for 1min. After cooling to room temperature, take 10μL of the supernatant after centrifugation and load it, and use a pre-stained protein molecular weight standard. The electrophoresis is set at about 150V for 100-120 minutes, and the electrophoresis can be stopped when bromophenol blue reaches the bottom of the gel. After the electrophoresis is completed, the gel and PVDF membrane (FFP30 / FFP33) are sequentially installed in the electrotransfer instrument, the membrane transfer current is 300mA, and the membrane transfer time is 100 minutes. After the membrane transfer is completed, add Western blocking solution, shake slowly (for example, at a speed of 20rpm) on a shaker, and block at room temperature for 60 minutes. Add HRP-conjugated Mouse anti His-Tag mAb (AE028) diluted with TBST buffer (dilution ratio 1:10000) and shake slowly on a shaker for 60 minutes. Use ECL (enhanced chemiluminescence) colorimetric reagent (purchased from Biolabs, catalog number: HR0340) and use a dedicated tableting cassette (FFC58 / FFC83) for tableting. The test results are as follows: Figure 6 shown. Figure 6 1 to 4 above represent standard proteins (Standard), which are 5μg, 2.5μg, 1.25μg, and 0.625μg per well, respectively. 5 to 9 represent recombinant protein GldK-IFN Domain and its dilution multiple samples (5 is the sample, and 6 to 9 are obtained by diluting the sample 2, 4, 8, and 16 times, respectively). Figure 6 As can be seen from the above, the expression level of the GldK-IFN Domain fusion protein band decreases as the amount of sample loaded decreases.

[0050] Example 2

[0051] The recombinant protein prepared in Example 1 was used to prepare a subunit oral vaccine of Flavobacterium columnaris, and its effect in preventing infection of Flavobacterium columnaris in mandarin fish was verified.

[0052] Experimental fish: 200 mandarin fish, with an average total length of 10±1cm and an average weight of 18±1g. After relevant virus detection and bacterial isolation confirmed that there were no pathogens, they were temporarily kept in fully automatic closed-circulation water barrels, with a stocking density of 30 per barrel, oxygenated, and a water temperature of 28±0.5℃.

[0053] Usage of oral vaccine: Add 1 mg of recombinant protein GldK-IFN Domain to every 40 kg of feed. Dissolve the recombinant protein GldK-IFN Domain in an appropriate amount of water, mix well, spray evenly on the feed, and dry.

[0054] Feeding amount for mandarin fish: Each mandarin fish weighs 18±1g. Feed 1% of the fish body weight once in the morning and evening, that is, the total amount of feed fed per day is 2% of the fish body weight.

[0055] Required consumables: 0.22μm filter screen, 1mL and 2.5mL syringes, 1.5mL EP tube, sterile saline, tissue homogenizer, heating rod, thermometer, and scoop net.

[0056] Experimental methods and results: Healthy mandarin fish were randomly divided into control group A and experimental group B. A and B were set up as a parallel group, with 50 fish in each group. In the first 3 days of the artificial infection experiment, the control group was fed with pure feed, while the experimental group was fed with mixed feed carrying oral vaccine for 3 consecutive days, once in the morning and once in the evening. On the 4th day, the control group and the experimental group were injected intraperitoneally with a volume of 0.4 mL / fish and a concentration of 4.4×10 6 The strain of Flavobacterium columnaris (isolated, identified and preserved by Wuhan Huayang Animal Health Group) was tested at 100 copies / μL. The fish were then routinely raised for 21 consecutive days. The incidence and mortality of the tested mandarin fish were observed and recorded daily, and the protective effect of the oral vaccine was calculated. The results are shown in Table 1, and the mortality curve is shown in Figure 7 .

[0057] Table 1 Statistical results of mortality in mandarin fish infected with Flavobacterium columnaris

[0058]

[0059] As can be seen from Table 1, after the oral vaccine was given to healthy mandarin fish without pathogens, they were artificially infected with Flavobacterium columnaris. The test mandarin fish began to die on the 3rd day after infection, and the 7th day after infection was the outbreak period. After that, the number of deaths began to decrease, and the number of deaths continued to be 0 from the 15th day to the 21st day. The protection rate of oral vaccine in Table 1 = (mortality rate of control group A - mortality rate of experimental group B) / mortality rate of control group A × 100%.

[0060] The above-described embodiments are only preferred embodiments of the present application and are not intended to limit the scope of protection of the present application. For any person skilled in the art, the present application may have various changes and modifications. Any simple equivalent changes and modifications made based on the scope of protection of the present application and the contents of the specification should be included in the scope of protection of the present application.

Claims

1. A recombinant protein of Flavobacterium columnaris, characterized in that The amino acid sequence of the recombinant protein of Flavobacterium columnaris is shown in SEQ ID No.

1.

2. A nucleic acid molecule encoding the recombinant protein of Flavobacterium columnaris according to claim 1.

3. The nucleic acid molecule according to claim 2, characterized in that The nucleotide sequence of the nucleic acid molecule is shown as SEQ ID No.

2.

4. A recombinant plasmid, characterized in that: The recombinant plasmid comprises the nucleic acid molecule according to claim 2 or claim 3.

5. A host cell, characterized in that The host cell comprises the recombinant plasmid of claim 4, or the nucleic acid molecule of claim 2 or claim 3 is integrated into the genome of the host cell.

6. The method for preparing the recombinant protein of Flavobacterium columnaris according to claim 1, characterized in that: The method comprises the following steps: constructing the recombinant plasmid according to claim 4, and obtaining the recombinant protein of Flavobacterium columnaris after the recombinant plasmid is transformed, cultured, positively screened, re-extracted, re-transformed, expanded, and induced to express.

7. The preparation method according to claim 6, characterized in that: The recombinant plasmid is obtained by connecting the nucleic acid molecule according to claim 2 or claim 3 to the plasmid pET-32a.

8. Use of the recombinant protein of Flavobacterium columnaris according to claim 1, the nucleic acid molecule according to claim 2, the recombinant plasmid according to claim 4, the host cell according to claim 5, or the preparation method according to claim 6 in preparing a subunit oral vaccine of Flavobacterium columnaris.

9. An oral subunit vaccine of Flavobacterium columnaris, characterized in that: The oral vaccine comprises the recombinant protein of Flavobacterium columnaris according to claim 1.

10. Use of the subunit oral vaccine of Flavobacterium columnaris according to claim 9 in the preparation of products for preventing and / or treating columnar disease in aquatic animals.